Galectin Therapeutics (NASDAQ:GALT) Upgraded by Wall Street Zen to “Hold” Rating
Wall Street Zen upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a research note released on Saturday. Separately, HC Wainwright initiated coverage on Galectin Therapeutics in a research note on Tuesday, June 17th. They issued a “buy” rating and a $6.00 price objective on the […]
Wall Street Zen upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a research note released on Saturday. Separately, HC Wainwright initiated coverage on Galectin Therapeutics in a research note on Tuesday, June 17th. They issued a “buy” rating and a $6.00 price objective on the […]
